{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:11:47Z","timestamp":1761883907992,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100019158","name":"Fundaci\u00f3n Espa\u00f1ola de Reumatolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019158","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019158","name":"Fundaci\u00f3n Espa\u00f1ola de Reumatolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019158","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.reumae.2020.06.010","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T17:07:39Z","timestamp":1616087259000},"page":"588-594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness, safety and economic analysis of Benepali in clinical practice"],"prefix":"10.1016","volume":"17","author":[{"given":"Marta","family":"Rojas-Gim\u00e9nez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Mena-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Mar\u00eda","family":"Romero-Barco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Manrique-Arija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Ure\u00f1a-Garnica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Diaz-Cordov\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Gabriel","family":"Jim\u00e9nez-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Fern\u00e1ndez-Nebro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2020.06.010_bib0005","first-page":"21","article-title":"Artritis reumatoide: Impacto de la enfermedad, an\u00e1lisis de los costes asociados y estudio del acceso a f\u00e1rmacos biol\u00f3gicos en las comunidades aut\u00f3nomas","volume":"15","author":"Garc\u00eda de Vicu\u00f1a","year":"2010","journal-title":"Rev Esp Econ Salud"},{"key":"10.1016\/j.reumae.2020.06.010_bib0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.reuma.2010.02.001","article-title":"[Systematic review: safety and efficacy of anti-TNF in elderly patients]","volume":"7","author":"Busquets","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2020.06.010_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.06.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.reumae.2020.06.010_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b3276","article-title":"Economics of biological therapies","volume":"339","author":"Kelly","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2020.06.010_bib0030","unstructured":"European Medicine Agency. Guideline on similar biological medicinal products 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf."},{"key":"10.1016\/j.reumae.2020.06.010_bib0035","doi-asserted-by":"crossref","first-page":"i46","DOI":"10.1136\/ard.59.suppl_1.i46","article-title":"Etanercept (Enbrel): update on therapeutic use","volume":"59","author":"Spencer-Green","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.06.010_bib0040","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00296-014-3080-5","article-title":"Etanercept biosimilars","volume":"35","author":"Azevedo","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2020.06.010_bib0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","article-title":"A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"76","author":"Emery","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.06.010_bib0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nbt0212-123","article-title":"Enbrel patent surfaces","volume":"30","author":"Harrison","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.reumae.2020.06.010_bib0055","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrd3749","article-title":"Can next-generation antibodies offset biosimilar competition?","volume":"11","author":"Mullard","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.reumae.2020.06.010_bib0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10067-011-1859-2","article-title":"The 2010 ACR\/EULAR classification criteria for rheumatoid arthritis in the Heinola inception cohort--diagnoses confirmed by long-term follow-up","volume":"31","author":"Kaarela","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2020.06.010_bib0065","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.06.010_bib0070","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.berh.2010.05.007","article-title":"Classification criteria for psoriatic arthritis and ankylosing spondylitis\/axial spondyloarthritis","volume":"24","author":"Rudwaleit","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.reumae.2020.06.010_bib0075","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informaci\u00f3n para las notificaciones de sospechas de reacciones adversas a medicamentos por parte de profesionales sanitarios. Available from: https:\/\/www.aemps.gob.es\/vigilancia\/medicamentosUsoHumano\/SEFV-H\/NRA-SEFV-H\/notificaSospechas-RAM-profSanitarios.htm#NSRAPS_que_RAM 2015."},{"key":"10.1016\/j.reumae.2020.06.010_bib0080","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2020.06.010_bib0085","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00296-017-3814-2","article-title":"Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study)","volume":"37","author":"Sellas","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2020.06.010_bib0090","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/art.21325","article-title":"Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index","volume":"53","author":"Cole","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2020.06.010_bib0095","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/acr.20575","volume":"63","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2020.06.010_bib0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11926-018-0799-0","article-title":"Review of biosimilar trials and data on etanercept in rheumatoid arthritis","volume":"20","author":"Chadwick","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.reumae.2020.06.010_bib0105","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reumae.2020.06.010_bib0110","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/ard.2007.087106","article-title":"Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study","volume":"68","author":"Combe","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.06.010_bib0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","article-title":"A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"76","author":"Emery","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.06.010_bib0120","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/kel245","article-title":"Drug survival in rheumatoid arthritis","volume":"45","author":"Mulherin","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2020.06.010_bib0125","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/ard.2008.091926","article-title":"European biologicals registers: methodology, selected results and perspectives","volume":"68","author":"Zink","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.06.010_bib0130","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s10067-018-4141-z","article-title":"Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data","volume":"37","author":"Khraishi","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2020.06.010_bib0135","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.06.010_bib0140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2020.06.010_bib0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2020.06.010_bib0150","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.16032","article-title":"Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study","volume":"178","author":"Girolomoni","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.reumae.2020.06.010_bib0155","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.20019","article-title":"Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2020.06.010_bib0160","first-page":"40","article-title":"The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis","volume":"25","author":"Dore","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2020.06.010_bib0165","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5114\/reum.2018.80710","article-title":"Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment","volume":"56","author":"Kowalik","year":"2018","journal-title":"Reumatologia"},{"key":"10.1016\/j.reumae.2020.06.010_bib0170","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","article-title":"The role of biosimilars in the treatment of rheumatic diseases","volume":"72","author":"D\u00f6rner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.06.010_bib0175","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1586\/1744666X.2015.1090313","article-title":"Biosimilars for the management of rheumatoid arthritis: economic considerations","volume":"11","author":"Gul\u00e1csi","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.reumae.2020.06.010_bib0180","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/s10198-014-0595-3","article-title":"Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries","volume":"15","author":"Brodszky","year":"2014","journal-title":"Eur J Health Econ"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321000563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321000563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:00:59Z","timestamp":1761879659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574321000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2173574321000563"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2020.06.010","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness, safety and economic analysis of Benepali in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2020.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2020.06.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}